



Universidade Estadual Paulista “Júlio de Mesquita Filho”
Faculdade de Odontologia de Araçatuba (FOA-UNESP)
Programa de Pós-Graduação em Odontologia
Área de Concentração: Estomatologia



VITOR BONETTI VALENTE

**Níveis dos hormônios do estresse no
microambiente: influência sobre a ocorrência
do tumor e modulação durante a carcinogênese
quimicamente induzida em ratos**



Araçatuba - SP

2016

VITOR BONETTI VALENTE

**Níveis dos hormônios do estresse no
microambiente: influência sobre a ocorrência
do tumor e modulação durante a carcinogênese
quimicamente induzida em ratos**

Dissertação apresentada à Faculdade de Odontologia do Câmpus de
Araçatuba - Unesp, para obtenção do Grau de “Mestre em Odontologia” –
Área de Concentração Estomatologia.

Orientador: Prof. Dr. Daniel Galera Bernabé

Co-orientadora: Profa. Dra. Sandra Helena Penha de Oliveira

Araçatuba - SP

2016

Catálogo na Publicação (CIP)

Diretoria Técnica de Biblioteca e Documentação – FOA / UNESP

V154n Valente, Vitor Bonetti.
Níveis dos hormônios do estresse no microambiente:
influência sobre a ocorrência do tumor e modulação durante
a carcinogênese quimicamente induzida em ratos / Vitor
Bonetti Valente. - Araçatuba, 2016
101f. ; il. ; tab. + 1 CD-ROM

Dissertação (Mestrado) – Universidade Estadual
Paulista, Faculdade de Odontologia de Araçatuba
Orientador: Prof. Daniel Galera Bernabé

1. Neoplasias 2. Carcinogênese 3. Estresse fisiológico
4. Norepinefrina 5. Corticosterona 6. Hormônio adrenocorti-
cotrópico 7. Fator neurotrófico derivado do encéfalo 8. Neo-
plasias de cabeça e pescoço I. Título

Black D6
CDD 617.63

DADOS CURRICULARES

DADOS PESSOAIS

VITOR BONETTI VALENTE

Nascimento.....: 12 de Maio de 1989

Ribeirão Preto/SP

Filiação.....: Vitor Valente Neto

Maria Neusa Bonetti Valente

DADOS CURRICULARES

2009-2013 Curso de Graduação em Odontologia pela Faculdade de Odontologia de Araraquara, Universidade Estadual Paulista “Júlio de Mesquita Filho” (FOAr - UNESP).

2012-2012 Curso de Aperfeiçoamento em Formação em Cirurgia Bucal pela Faculdade de Odontologia de Araraquara, Universidade Estadual Paulista “Júlio de Mesquita Filho” (FOAr - UNESP).

2014-2016 Curso de Pós-Graduação em Odontologia, na Área de Estomatologia, nível de Mestrado, pela Faculdade de Odontologia de Araçatuba, Universidade Estadual Paulista “Júlio de Mesquita Filho” (FOA - UNESP).

DEDICATÓRIA

DEDICATÓRIA

Dedico este estudo...

***...à todos os pacientes que vivem ou que já viveram
a experiência de adoecer com o câncer...***

AGRADECIMENTOS

AGRADECIMENTOS

AGRADEÇO...

À **Deus**, por me proporcionar a Sua paz e serenidade, essenciais para enfrentar e superar todos os desafios. Obrigado por me acompanhar em TODOS os momentos e por me permitir chegar até aqui.

Aos meus pais, **Vitor Valente** e **Maria Neusa**, pelo amor incondicional, zelo, amparo, carinho, dedicação, atenção e esforços voltados à minha formação religiosa, humana, ética e profissional. À eles, minha eterna gratidão e todo meu amor. Obrigado por me apoiarem na realização deste trabalho e na conclusão de mais uma etapa.

Às minhas irmãs caçulas que amo muito, **Ana Carolina** e **Ana Julia** pela atenção, companheirismo e pelo apoio em todos os momentos da minha vida. Muito obrigado por me presentearem constantemente com a alegria contagiante que vocês duas têm, que deixa a vida bem mais “leve” quando podemos estar juntos.

Aos meus avós paternos, **Victor** e **Wilman**, e maternos, **Raeder** e **Clélia** (Mami), minha tia e madrinha **Clélia** (Tata), e meus **tios, tias, primos e primas**, todos sempre solícitos naquilo que melhor poderiam oferecer para me apoiar na busca dos meus sonhos e objetivos. Muito obrigado pelo incentivo de vocês.

Aos meus grandes companheiros, amigos de infância e irmãos “do peito”, **Pedro Peres, Leandro Pippa** e **Felipe Matioli**, que sempre acompanham meus

caminhos, torcem e vibram por mim. Obrigado por estarem ao meu lado em mais uma conquista, e por serem tão acolhedores nos meus retornos à Ribeirão Preto (SP) sempre que é possível realizar uma reunião da “máfia”.

À todos os amigos da **Turma 84**, formados pela Faculdade de Odontologia de Araraquara, Universidade Estadual Paulista “Júlio de Mesquita Filho” (FOAr – UNESP), em especial, **Patrícia Lima, Welton Arita, Túlio Morandin, Rafael Piai, Vitor Racca, Sabrina Neri e Mônica Irma**, pelos momentos saudosos e pelas lembranças perpétuas das experiências vividas nos anos da graduação, e aos amigos **docentes** e **servidores** técnico-administrativos daquela instituição, em especial, das disciplinas de Diagnóstico Bucal e Estomatologia. A professora Dra. **Cláudia Maria Navarro**, minha primeira orientadora na área de diagnóstico bucal, com quem pude desenvolver meu trabalho de conclusão de curso (TCC) por meio do estágio de iniciação científica. Muito obrigado pelos estímulos que despertaram em mim grande interesse pela “vida acadêmica” e pelos anos de convivência e aprendizado. As professoras Dra. **Mirian Aparecida Onofre**, Dra. **Elaine Maria Sgavioli Massucato** (diretora da FOAr – UNESP) e Dra. **Andreia Bufalino**, e a funcionária **Meire Pipoli** por toda ajuda, parceria, contribuição e aprendizado gerado nas atividades acadêmicas desenvolvidas nesses anos de convivência dentro da universidade, quanto pelos momentos de descontração e alegria fora dela.

À Faculdade de Odontologia do Câmpus de Araçatuba, da Universidade Estadual Paulista “Júlio de Mesquita Filho” (FOA – UNESP), representada pelos amigos e companheiros, diretor Prof. Dr. **Wilson Roberto Poi** e vice-diretor Prof. Dr. **João Eduardo Gomes Filho**, ao programa de pós-graduação *stricto sensu*

em Odontologia, coordenado pelo Prof. Dr. **André Luiz Fraga Briso**, e à área de concentração em Estomatologia, coordenada com brilhantismo pelo amigo Prof. Dr. **Glauco Issamu Miyahara**, pela oportunidade de realizar este curso de pós-graduação na referida instituição de ensino.

Ao Departamento de Patologia e Propedêutica Clínica, representado pela chefe Profa. Dra. **Leda Maria Pescinini Salzedas**, vice chefe Prof. Dr. **Marcelo Macedo Crivelini** e pelas assessoras administrativas **Adriana de Paula** e **Silva Rahal Leal**, ao Departamento de Ciências Básicas, representado pela chefe Profa. Dra. **Doris Hissako Sumida**, vice chefe Profa. Dra. **Alaíde Gonçalves** e assessora administrativa **Eliseide Maria Navega**, e à empresa Merck Millipore Brasil, com sede em Barueri (SP), representada pelo Prof. Dr. **Matheus Corrêa Costa**, pelo fornecimento das instalações e infraestrutura para a realização dos experimentos idealizados para este estudo.

Aos excelentíssimos professores, Dr. **Éder Ricardo Biasoli**, Dr. **Glauco Issamu Miyahara**, Dr. **Daniel Galera Bernabé** e Dra. **Kellen Cristine Tjioe**, e a funcionária **Marli dos Santos**, da disciplina de Estomatologia, e à todos os companheiros **docentes** e **servidores** técnico-administrativos do Departamento de Patologia e Propedêutica Clínica e do Departamento de Ciências Básicas pela convivência e amizade e pela parceria e disponibilidade.

Ao Centro de Oncologia Bucal (COB) da FOA – UNESP, supervisionado pelo professor Dr. **Glauco Issamu Miyahara**, pelo acolhimento e oportunidade ímpar do aprendizado, tanto técnico-científico quanto pela troca de experiências humanas diversas junto aos pacientes que fazem ou que fizeram o tratamento

para o câncer. Aos servidores técnico-administrativos do COB, **Jane Fátima, Jefferson Teixeira, Janaína Zavitoski, Francisco Collado, Sebastião Neto, Suzy Freitas, Regiane Nogueira, Daniene Ribeiro, Anne Cocato e Gabrielle Duarte** pela disponibilidade, amizade, convívio diário, e pela ajuda nas diretrizes do tratamento oncológico e do recrutamento de pacientes para pesquisa.

Aos servidores técnico-administrativos que trabalham na Seção de Pós-Graduação da FOA - UNESP, **Lilian, Cristiane e Valéria** por toda ajuda, auxílio e colaboração prestados com muita eficiência e dedicação. Aos funcionários da biblioteca da FOA – UNESP, em especial, a **Ana Cláudia** pela atenção e ajuda imprescindível com a formatação deste trabalho.

Ao meu orientador e amigo, Prof. Dr. **Daniel Galera Bernabé**, docente da disciplina de Estomatologia, exemplo de caráter, ética e de comprometimento profissional na *busca incansável de um ideal*, pela oportunidade de desenvolver este trabalho de pesquisa. Pela sua orientação segura, com respeito, dedicação, paciência e tolerância, compreensão e disponibilidade. Agradeço, imensamente, todo apoio concedido. Muito obrigado pelo acolhimento, por confiar em mim, e também por todos os estímulos, fundamentais para que eu pudesse desenvolver um aprendizado ímpar no campo científico como pesquisador (“em formação”). Espero ter atendido e correspondido às suas expectativas e anseios. Gratidão e reconhecimento por tudo. TUDO.

À minha co-orientadora e amiga, Profa. Dra. **Sandra Helena Penha de Oliveira**, pela sua co-orientação, estímulos, confiança, disponibilidade, apoio e “gigantesco” suporte laboratorial (que permitiu o alojamento dos animais desta

pesquisa durante o período de carcinogênese bucal e a realização dos ensaios de PCR em tempo real e ELISA). Muito obrigado pela sua grande parceria e por toda colaboração.

Ao professor e médico veterinário Dr. **Paulo Sérgio Patto dos Santos** e a sua ex-aluna, orientada de doutorado, a médica veterinária Dra. **Joana Zafalon Ferreira**, ambos da Faculdade de Medicina Veterinária, Câmpus de Araçatuba (FMVA – UNESP), pelo suporte ambulatorial e auxílio com a anestesia dos animais para a realização das biópsias linguais. Aos médicos veterinários Dr. **Caio Galera Bernabé** (Clínica Veterinária CardioMais, São José do Rio Preto, SP, Brasil) e Dr. **Fábio Nascimento Franco** (Clínica Veterinária Gaiavet, São José do Rio Preto, SP, Brasil) por esclarecerem minhas dúvidas em relação aos procedimentos anestésicos e farmacológicos preconizados para os animais que participaram desta pesquisa. Muito obrigado pela receptividade.

Ao professor Dr. **Matheus Corrêa Costa** (Merck S.A., Barueri, SP, Brasil) pelo grande auxílio com as dosagens dos hormônios pelo método de dosagem de múltiplos analitos. À professora Dra. **Ana Cláudia Stevanato Nakamune** por me ajudar com a dosagem de proteínas totais das amostras.

Aos professores e amigos Dra. **Ana Maria Pires Soubhia** e Dr. **Glauco Issamu Miyahara**, pela disponibilidade e grande contribuição com a análise histopatológica do trabalho. Aos amigos e técnicos do laboratório de patologia, **José Marcelo Tramarin** (Gordo) e **Giseli Mitsuy Kayahara**, por me ajudar com a organização e também com o processamento histopatológico das lâminas. O método proposto por vocês funcionou muito bem comigo. Muito obrigado.

Ao professor Dr. **Luciano Tavares Ângelo Cintra** pela sua orientação na captura das imagens histopatológicas e medida microscópica da espessura dos tumores.

Às professoras Dra. **Maria Lúcia Marçal Mazza Sundefeld** e Dra. **Marisa de Andrade** (Mayo Clinic, Rochester, MN, Estados Unidos) por contribuírem com a análise estatística do trabalho.

Aos meus queridos amigos da pós-graduação em Estomatologia, **Flávia Verza** (Sister!!! Muito obrigado por me receber tão bem em Araçatuba e por estar sempre ao meu lado e me apoiando em todas as ocasiões!!!), **Lígia Lavezo**, **Gláucia Soares**, **Neliana Salomão**, **Maurício Fabiano**, **Ingrid Santos**, **Daniela Bastos**, **Bruna Sarafim**, **Ketelin Dal Pra**, **Aneliza Moraes**, **Jéssica Figueira** e **Saygo Tomo**, pelo convívio próximo nestes dois anos e meio de mestrado. Muito obrigado por estarem junto comigo caminhando para a reta final desta etapa, que reuniu incontáveis momentos de felicidade, porém também de dificuldades. Gratidão a cada um de vocês por todo carinho, atenção e apoio dispensados. Aos **amigos** da pós-graduação das demais áreas do programa de Odontologia pela torcida. Muito obrigado.

Aos meus queridos amigos da pós-graduação e graduação que “habitam” o laboratório de Farmacologia, **Aline Satie Takamiya** (Alininha Pós-doc!!! Muito obrigado por todos os conselhos de “mãe” e também pelo apoio incondicional de sempre!!!), **Caril Amaral**, **Victor Balera** (Vitão!), **Carluci Beltran**, **Fernanda Demarqui**, **Simone Potje**, **Jéssica Troiano** e **Murilo Graton** (Murilão!) por me ajudarem nas dúvidas e dificuldades que encontrei no laboratório.

Aos meus queridos e estimados amigos da graduação, em especial, os estagiários da disciplina de Estomatologia, **Felipe Yudi** (Felipão! Muito obrigado pela ajuda, por ser meu “braço-direito” e enfrentar comigo todas as dificuldades encontradas na execução laboratorial deste trabalho!), **Lia Kobayashi**, **Daniella Cantieri**, **Jéssica Bugiga**, **Heitor Cecílio**, **Karla Zancan** e **Camila Moura** pela convivência e por me concederem a oportunidade diária de aprender com vocês. Às alunas **Isadora Victorino** e **Camila Nathiele** por me auxiliar nas biópsias linguais dos animais desta pesquisa e aos alunos **João Pedro**, **Karina Andrade**, **Camila Guerra** e **Lucas Seraphim** pela colaboração em atividades acadêmicas realizadas em conjunto.

Aos **animais** utilizados nesta pesquisa, que “doaram” a própria vida para a construção de um novo horizonte científico.

À **CAPES/DS** (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), pelo apoio financeiro por meio da bolsa de estudo concedida.

À **todas** as pessoas envolvidas que, direta ou indiretamente, contribuíram de alguma forma para a realização deste trabalho.

ΕΠΙΓΡΑΦΕ

EPÍGRAFE

“Embora ninguém possa voltar atrás e fazer um novo começo, qualquer um pode começar agora e fazer um novo fim.”

Francisco Cândido Xavier

RESUMO

Valente VB. Níveis dos hormônios do estresse no microambiente: influência sobre a ocorrência do tumor e modulação durante a carcinogênese quimicamente induzida em ratos. [dissertação]. Araçatuba: Faculdade de Odontologia da Universidade Estadual Paulista; 2016.

Resumo

Evidências mostram que os hormônios relacionados ao estresse podem influenciar a progressão do câncer, mas o papel destes mediadores sobre o processo de carcinogênese no microambiente tecidual, em condições naturais, é pouco compreendido. Neste estudo, nós utilizamos um modelo de carcinogênese bucal em ratos para testar a hipótese de que os níveis de hormônios relacionados ao estresse no microambiente tecidual em condições naturais (sem estresse) pré-indução carcinogênica influenciam a ocorrência e progressão do carcinoma espinocelular (CEC) de língua. Quarenta e oito ratos machos Wistar foram submetidos a uma biópsia de tecido lingual normal previamente à indução carcinogênica e os níveis teciduais de norepinefrina, corticosterona, ACTH e BDNF foram mensurados. Três semanas depois os animais foram tratados com o carcinógeno químico 4-nitroquinolina-1-óxido (4NQO) por 20 semanas e a ocorrência de CEC ou Leucoplasia (lesão precursora do CEC) na língua foi analisada microscopicamente. Níveis basais aumentados pré-carcinogênese de norepinefrina e BDNF e níveis reduzidos de corticosterona foram preditivos para ocorrência de CEC. Níveis basais elevados de norepinefrina foram associados à uma expressão reduzida de RNAm para CDKN2a-p16 nos CECs. Níveis teciduais de corticosterona e BDNF nas leucoplasias e corticosterona no CEC foram significativamente mais elevados em relação a mucosa normal pré-carcinogênese. Níveis elevados de norepinefrina no microambiente dos CECs foram associados a um maior volume e espessura do tumor. Da mesma forma, níveis elevados de norepinefrina, ACTH e BDNF no CEC foram associados a uma menor intensidade do infiltrado linfoplasmocitário subjacente ao tumor. Além disso, maior expressão de RNAm para IL-6 no CEC foi correlacionada à níveis elevados de corticosterona pós-carcinogênese. Este estudo mostra as primeiras evidências in vivo de que os níveis basais de hormônios do estresse no microambiente do tecido normal podem ser preditivos para a incidência do câncer quimicamente induzido. Além disso, a ação do carcinógeno pode modular os níveis hormonais no microambiente tecidual e estes podem estar associados à progressão do tumor. Em suma, estes dados sugerem que a susceptibilidade ao início e progressão do carcinoma quimicamente induzido pode ser diretamente influenciada por diferenças individuais endócrinas no microambiente pré-carcinogênese.

Palavras-chave: Neoplasias, carcinogênese, estresse fisiológico, norepinefrina, corticosterona, hormônio adrenocorticotrópico, fator neurotrófico derivado do encéfalo, neoplasias de cabeça e pescoço

ABSTRACT

Valente VB. Stress hormones levels in the microenvironment: influence on tumor occurrence and modulation during chemically induced carcinogenesis in mice. [dissertation]. Araçatuba: UNESP – São Paulo State University; 2016.

Abstract

Evidence show that stress-related hormones may influence cancer progression, but their role in tissue microenvironment on the carcinogenesis is poorly understood. In this study, we have used an oral carcinogenesis model in rats to test the hypothesis that stress-related hormones levels in the tissue microenvironment in natural conditions pre-carcinogenic induction could influence the oral squamous cell carcinoma (OSCC) occurrence and progression. Forty-eight male Wistar rats were underwent to a normal tongue tissue biopsy before carcinogenic induction and tissue levels of norepinephrine, corticosterone, ACTH and BDNF were measured. Three weeks later the animals were treated with chemical carcinogen 4-nitroquinoline-1-oxide (4NQO) for 20 weeks and the OSCC or oral leukoplakia (non-cancerous lesions) occurrence into tongue was evaluated. Increased concentrations of norepinephrine and BDNF, and reduced corticosterone levels in the pre-carcinogen microenvironment were predictive for OSCC occurrence. Increased pre-carcinogen norepinephrine concentrations were associated to a CDKN2a-p16 mRNA lower expression in OSCCs. Tissue levels of corticosterone and BDNF in oral leukoplakia and corticosterone in OSCC were significantly higher than pre-carcinogenesis normal mucosa. Increased norepinephrine concentrations in OSCC microenvironment were associated to a higher tumor volume and thickness. Likewise, increased levels of norepinephrine, ACTH and BDNF in OSCC were associated to a lesser intensity of the lymphoplasmocytic infiltrate underlying to tumor. Furthermore, IL-6 mRNA enhanced expression was correlated to increased corticosterone levels post-carcinogenesis. This study shows the first *in vivo* evidence that pre-carcinogen stress hormones levels in the microenvironment of the normal tissue may be predictive for chemically induced cancer occurrence. Moreover, the carcinogen action can modulate hormonal levels in the tissue microenvironment, which can be associated to tumor progression. In short, these data suggest that the susceptibility to onset and progression of chemically induced carcinomas may be directly influenced by endocrine individual differences in pre-carcinogenesis microenvironment.

Keywords: Neoplasias, carcinogenesis, physiological stress, norepinephrine, corticosterone, adrenocorticotrophic hormone, brain-derived neurotrophic factor, head and neck neoplasias

LISTA DE FIGURAS

LISTA DE FIGURAS

Page 38

Figure 1. Illustrative representation of experimental design and study phases.

Page 41

Figure 2. Anesthetic induction. A. Rat inside of Induction-chamber. B. Loss of muscular tonus (animal in the ventral decubitus position). C. The rat was removed from induction-chamber and maintained under anesthesia with an adapted face mask.

Page 42

Figure 3. Tongue biopsy pre-carcinogenic induction. A. Normal tongue mucosa. B. Incision with a 4 mm circular manual punch. C. Removal of the fragment. D. Surgical wound. E. Sutures. F. Lingual mucosa fragment for laboratorial analyses.

Page 51

Figure 4. Clinical and histopathological features of oral leukoplakia and OSCC developed after chemically induced carcinogenesis by 4NQO (original magnification - 100x). (A) Small irregular yellowish-white plates. (B) Hyperplastic epithelium with mild dysplasia and hyperkeratosis. (C) Large heterogeneous white plate. (D) Moderate epithelial dysplasia with mild chronic inflammatory infiltrate. (E) Ulcerative lesion surrounded by few white areas. (F) Well-

differentiated OSCC with intense inflammatory infiltrate underlying to neoplastic area. (G) Extensive ulcerative lesion reaching half of the tongue. (H) Highly infiltrative well-differentiated OSCC.

Page 53

Figure 5. Simple linear regression analysis among pre-carcinogen norepinephrine (A), corticosterone (B), ACTH (C) and BDNF (D) concentrations, and oral leukoplakia and OSCC occurrence. Pre-carcinogen norepinephrine and BDNF levels in the tongue microenvironment predicted oral cancer (* $p < 0.05$). Student's test- t between stress-related hormones levels means pre-carcinogenic induction, which were used to produce respective bar graphs; * $p < 0.05$.

Page 58

Figure 6. Student's test- t between pre- and post-carcinogen levels of norepinephrine (A), corticosterone (B), ACTH (C) and BDNF (D). Increased post-carcinogen corticosterone concentrations were found in the tumor and leukoplastic lesions (* $p < 0.05$). Higher post-carcinogen BDNF levels were found only in the leukoplastic lesions compared to pre-carcinogen normal mucosa; * $p < 0.05$.

Page 59

Figure 7. Correlation analysis showing a positive correlation between pre-carcinogen stress-related hormones levels (A, C, E, G, I and K; * $p < 0.001$). A positive correlation was also observed in the post-carcinogen concentrations of

norepinephrine vs ACTH (D; $*p<0.001$), corticosterone vs ACTH (H; $*p=0.035$) and ACTH vs BDNF (L; $*p<0.001$).

LISTA DE TABELAS

LISTA DE TABELAS

Page 54

Table I. Pre-carcinogen stress-related hormones in the tongue microenvironment and OSCC occurrence risk.

Page 56

Table II. Associations among pre-carcinogen stress-related hormones and clinicopathological variables and molecular features.

Page 61

Table III. Association among post-carcinogen stress-related hormones and clinicopathological variables and molecular features.

LISTA DE ABREVIATURAS

LISTA DE ABREVIATURAS

11 β HSD2 = 11 β -hydroxysteroid dehydrogenase type II

4NQO = 4-nitroquinoline-1-oxide

ACTH = adrenocorticotrophic hormone

AKT = protein kinase B

BDNF = brain-derived neurotrophic factor

C57BL6/J = C57 black 6/J

CA = California

cAMP = adenosina 3',5'-monofosfato cíclico

CDK-4 = cyclin-dependent kinase 4

CDK-6 = cyclin-dependent kinase 6

CDKN2A = cyclin-dependent kinase Inhibitor 2A

cDNA = complementary deoxyribonucleic acid

CNS = central nervous system

Co. = company

COX-2 = cytochrome c oxidase subunit 2

CRF = corticotropin-releasing factor

CV = coefficient of variation

DNA = deoxyribonucleic acid

E-cadherin = epithelial cadherin

ECM = extracellular matrix

eg. = for example

EGF = epidermal growth factor

ELISA = enzyme-linked immunosorbent assay

FGF = fibroblast growth factor

GA = Georgia

H&E = hematoxylin and eosin

HGF = hepatocyte growth factor

HPA = hypothalamic-pituitary-adrenal

IL-12 = interleukin 12

IL-6 = interleukin-6

Inc. = Incorporation

LASSO = least absolute shrinkage and selection operator

Ltd. = limited

MA = Massachusetts

MAPK = mitogen-activated protein kinase

MDMD 2 = murine double minute 2

MMP-2 = matrix metalloproteinase 2

MMP-9 = matrix metalloproteinase 9

MMPs = matrix metalloproteinases

MO = Missouri

mRNA = messenger ribonucleic acid

NC = North Carolina

NIH = National Institutes of Health

NK = natural killer

No = number

OSCC = oral squamous cell carcinoma

PBS = phosphate-buffered saline

PKA = protein kinase A

RNA = ribonucleic acid

RNase = ribonuclease

RQ = relative quantity

RT = room temperature

RT-PCR = reverse transcription polymerase chain reaction

SNS = sympathetic nervous system

SP = São Paulo

St. = Saint

Stat 3 = signal transducer and activator of transcription 3

Statistical Analysis System = SAS

TGF- α = transforming growth factor alpha

TGF- β = transforming growth factor beta

Th1 = type 1 helper cells

TrkB = tyrosine receptor kinase B

Twist = twist-related protein 1

TX = Texas

UK = United Kingdom

UNESP = Univ Estadual Paulista

USA = United States of America

UV = ultraviolet

VEGF = vascular endothelial growth factor

Wnt-1 = proto-oncogene protein Wnt-1

SUMÁRIO

1. Introdução	32
2. Material e Método	37
3. Resultados	50
4. Discussão	63
Referências	74
Anexo A	83
Anexo B	85

INTRODUÇÃO

Introduction*

Studies have shown that hormones resulting from chronic stress may influence cancer progression (1-4). The two main pathways that have been investigated for mediating the emotional stress effects on cancer are the hypothalamic-pituitary-adrenal (HPA) axis (5) and sympathetic nervous system (SNS) (6). HPA axis activation occurs when neurons localized in the paraventricular nucleus secrete corticotropin-releasing factor (CRF); then, CRF stimulates the secretion of adrenocorticotrophic hormone (ACTH), which induces the adrenal glands to synthesize cortisol (2,5). In parallel, SNS activation during chronic stress can induce a dysregulated production of catecholamines norepinephrine and epinephrine by the central nervous system (CNS) and adrenal gland (2,6).

Stress hormones act on tumor cells deregulating the production of cytokines, chemokines and growth factors, which are related with cancer progression (1-4). Studies have shown that norepinephrine and epinephrine enhance the expression of genes involved in tumor angiogenesis and proliferation such as vascular endothelial growth factor (VEGF) (7,8) and interleukin-6 (IL-6) (9-11), as well as deregulate the production of matrix metalloproteinases (MMPs) (12-14) types 2 and 9; proteins that increase tumor invasion and metastasis occurrence. Catecholamines derived from SNS hyperactivity suppress the cytotoxic T lymphocytes and natural killer (NK) cell

*Normalização segundo o periódico “Carcinogenesis” (Anexo B)

responses (15), and activate the expression of genes by oncogenic virus (16). Pre-clinical studies have demonstrated that stress-related hormones can affect ovarian (7,8,10,12,13), breast (17), lung (18) and colon (19) cancer progression. Clinical investigations have showed that patients with advanced-stage ovarian (9), colorectal (20), and head and neck (21) cancer have significant increased cortisol levels compared to patients with early-stage disease or healthy controls. However, there are no clinical evidences that stress-related hormones levels can influence cancer occurrence. Few pre-clinical investigations have demonstrated that stress-related hormones also may act on the regular cells promoting cancer development (22,23). Long exposures in dose response experiments with norepinephrine and epinephrine induced significant increases in the tumorigenicity of mouse fibroblasts (22). Chronic stress promoted tumor development (lymphomas and sarcomas) in C57BL6/J male mice by the attenuation of p53 protein levels and transcriptional activity, which were mediated by increased levels of corticosterone in the serum (23).

Brain-derived neurotrophic factor (BDNF) is a neurotrophin distributed mainly in the CNS, where it act as trophic factor for dopaminergic and cholinergic neurons. Evidences have shown that BDNF expression in the CNS can be modulated by stress (24). BDNF and its receptor TrkB have an important role as autocrine modulators being expressed in several organs (24). Acute and chronic stress may increase plasma BDNF levels in pre-clinical models (25,26). Studies have demonstrated that BDNF expression is involved with tumor cell proliferation and invasion process (27,28). BDNF has been identified in head and neck (27),

liver (28), prostate (29) and bladder (30) cancers, suggesting a role of neurotrophins in cancer development and progression.

Tumor microenvironment is an aberrant tissue environment composed by tumor epithelial cells and specialized mesenchymal cells (inflammatory cells, myoepithelial and endothelial cells, myofibroblasts and fibroblasts) surrounding by an altered extracellular matrix (ECM), which plays an important role in cancer development and progression (31,32). Interactions between the mesenchymal and epithelium cells through the morphogenic factors (eg. Wnt-1, HGF and TGF- β) and growth factors (eg. FGF, EGF and TGF- α) secretion are altered in carcinomas and can influence the carcinogenesis (32). Although evidences show that stress and its neurohormones may influence cancer progression, there are no studies that have assessed the stress-related hormones levels in the tissue microenvironment before cancer and their influence on carcinogenesis and tumor progression. Chemical carcinogens exposure may affect important cellular metabolic functions as the production and release of different biological mediators (33,34). However, it is unclear how chemical carcinogens could act modulating stress hormones concentrations in the tumor microenvironment under carcinogenesis induction.

In the present study, we have used a pre-clinical oral carcinogenesis model to test the hypothesis that stress-related hormones concentrations in the tissue microenvironment before tumor induction could influence the cancer occurrence, clinicopathological variables and tumor progression-related genes expression. Furthermore, the local concentrations of these mediators were compared pre- and post-carcinogenesis induction and hormones levels in cancer

microenvironment were analyzed for association to tumor progression-related variables.

MATERIAL E MÉTODO

Materials and methods

1. Experimental animals and maintenance conditions

All experimental procedures involving animals were in agreement to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Welfare Committee at the Araçatuba Dental School (UNESP - Univ Estadual Paulista, Araçatuba, SP, Brazil - Process 2014-00816 – ANEXO A). Forty-eight male Wistar rats, 12 weeks old, weighing between 250 and 300 g, were used for the experiments. The animals were group-housed, 3 per cage (25.9 × 47.6 × 20.9 cm, polypropylene), and kept in a constant room temperature (RT) (25 ± 2 °C), humidity (55 ± 3 °C), under a 12-hour light-dark cycle, and received *ad libitum* access to standard food (Purina, Paulínia, SP, Brazil) and drinking water.

2. Experimental design

In order to assess whether the stress-related hormones concentrations in the tongue microenvironment could influence oral carcinogenesis chemically induced, the experiments were divided in three main steps. In phase 1, all animals were underwent to a lingual tissue collection for characterizing the stress-related hormones levels in the microenvironment (pre-carcinogen hormonal levels). In phase 2, the same animals who have passed through phase 1 were underwent to chemically induced oral carcinogenesis. In phase 3, after 20 weeks of oral carcinogenesis, all animals were euthanized for evaluation of oral cancer occurrence and stress-related hormones concentrations in the microenvironment (post-carcinogen hormonal levels) (Figure 1).




Figure 1. Illustrative representation of experimental design and study phases.

3. Individual characterization of the stress-related hormones levels in the tongue microenvironment pre-carcinogen induction

3.1. Anesthetic induction.

In the first phase of the study, to characterize individual differences in the stress-related hormones concentrations in the tongue microenvironment, all animals were submitted to a lingual biopsy under inhalatory anesthesia. The anesthetic induction was performed by induction-chamber (Figures 2A and 2B) containing isoflurane (Cristália, Itapira, SP, Brazil), with inspired fraction of 5%, diluted in 100% oxygen with 3L/min flow. An open non-rebreathing circuit (Anesthesia equipment Nikkei K – Takaoka, São Paulo, SP, Brazil) was used until the loss of muscular tonus (animal in the ventral decubitus position) (Figure 2B). In sequence, the rat was removed from induction-chamber and maintained under anesthesia with an adapted face mask, connected to the same induction system (Figure 2C). The anesthetic maintenance was performed with inspired fraction of 3% and with oxygen flow of 2L/min.

3.2. Tongue biopsy pre-carcinogenic induction.

With the animal anesthetized (Figure 2C), the tongue was tractioned using a suture thread (Figure 3A) and a biopsy was performed on the posterior region of tongue dorsum, with a 4 mm circular manual punch (Figure 3B) allowing the removal of a lingual mucosal fragment (Figures 3C, 3D and 3E). This region of the lingual mucosa was selected for the measurements of stress-related hormones, since it is the main location where carcinomas are developed in the chemically induced oral carcinogenesis model used in this study. After removing

the tongue fragment, the surgical wound was sutured with 4.0 silk thread (Ethicon Johnson & Johnson, São José dos Campos, SP, Brazil) (Figure 3F). The lingual mucosa sample was rinsed with physiological saline solution, and then stored at -80°C for hormones measurements. In the postoperative period, the animals were fed with softened rat chow, which was previously crunched in drinking water.



Figure 2. Anesthetic induction. A. Rat inside of Induction-chamber. B. Loss of muscular tonus (animal in the ventral decubitus position). C. The rat was removed from induction-chamber and maintained under anesthesia with an adapted face mask.




Figure 3. Tongue biopsy pre-carcinogenic induction. A. Normal tongue mucosa. B. Incision with a 4 mm circular manual punch. C. Removal of the fragment. D. Surgical wound. E. Sutures. F. Lingual mucosa fragment for laboratorial analyses.

3.3. Measurements of the stress-related hormones concentrations in the tongue microenvironment.

Sample preparation. For baseline stress-related hormones concentrations measurements in the tongue microenvironment, normal lingual mucosal samples were triturated in a PBS buffer containing a specific protease inhibitor cocktail (Calbiochem, San Diego, CA, USA). The tissue was rinsed with 1X PBS, and homogenized in 500 μ L of protease inhibitor cocktail. Then, the homogenates were centrifuged for 5 minutes at 5000 xg. Lastly, the supernatant of each sample was removed, aliquoted and then stored at -80°C for stress-related hormones measurements.

Analysis of norepinephrine levels. Norepinephrine levels were quantified using a commercially available specific kit (Catalog. No: U0907Ge; Wuhan Elab Science Co. Ltd., China) through the enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's recommendations. The assay was performed in triplicate. The minimum detectable concentration of the assay (assay sensitivity) is less than 7.5 pg/mL, and intra-assay and inter-assay coefficient of variation (CV) are <4.3% and 7.5%, respectively.

Analysis of corticosterone, ACTH and BDNF levels. The corticosterone, ACTH and BDNF levels in normal lingual mucosa were measured using the Milliplex Multi-Analyte Profiling method, through Luminex xMAP™ technology. To perform these immunoassays, specific kits Milliplex™ (ACTH, corticosterone, Catalog. No: RSHMAG-69K; BDNF, Catalog. No: RPTMAG-86K; Millipore, Billerica, MA, USA) containing a 96-well plate each one were used. Firstly, 200 μ L of assay buffer were added per well, and then the plates were shaken for 10

minutes. After decanting in RT, 25 μ L of standard or control were added to appropriated wells, 25 μ L of assay buffer were added to background and sample wells, and 25 μ L of matrix were added to background, standards and control wells. After, 25 μ L of samples were added to sample wells, and 25 μ L of beads were added to each well. The plates were incubated overnight for 18 hours at 4°C with shaking. Well contents were removed and they were washed 3X with 200 μ L of wash buffer. Then, 50 μ L of detection antibodies were added per well and the plates were incubated for 1 hour at RT. Afterward, 50 μ L of streptavidin-phycoerythrin were added per well. The plates were incubated for more 30 minutes at RT, and then well contents were removed and they were washed 3X with 200 μ L of wash buffer. Lastly, 100 μ L of sheath fluid were added per well. All assays were run in triplicate. The assay sensitivities are 2914 pg/mL for corticosterone, 0.9 pg/mL for ACTH and 0.38 pg/mL for BDNF. The intra-assay and inter-assay CVs are <10% for corticosterone and ACTH, 1.7% and 12.2% for BDNF, respectively. The hormonal levels were quantified on the MAGPIX-XPONENT™ equipment (Millipore, Austin, TX, USA), and the data were analyzed using the Milliplex Analyst 5.1 software (Millipore, Billerica, MA, USA).

Normalization of hormonal levels. Total protein concentration in the tissue homogenates was measured using the method of Lowry et al. (35), and the data were used to normalize the stress-related hormones levels. The hormonal levels were expressed as pg/ μ g in 1 mL of tissue homogenate.

4. Oral carcinogenesis induction

Three weeks after the biopsy, all animals were anesthetized and checked before the start of oral carcinogenesis induction. All animals exhibited the dorsum

surface of the tongue healed, and thereby they were included in the next phase of study (chemically induced oral carcinogenesis). For tumor induction, animals were treated with 50 ppm of 4-nitroquinoline-1-oxide (4NQO) (Sigma-Aldrich, St. Louis, MO, USA) diluted in drinking water. All animals had free access to consume water with the carcinogen solution, which was replenished twice a week. In agreement with a previous study (36), animals were euthanized (by decapitation) after a 20 weeks period of carcinogenic induction. Then, in the third phase of the study, the tongues with induced-carcinogen lesions were extracted to perform histopathological analysis, measurements of the stress-related hormones levels in the microenvironment, and gene expression analysis by RT-PCR assay.

5. Histopathological analysis

For histopathological examination, the tongues were longitudinally sectioned and the tissues were fixed in 10% buffered formaldehyde for 48h, submitted to the routine laboratory procedures, embedded in paraffin blocks (sectioned at 4 μ m), and stained with Hematoxylin and Eosin (H&E) (Merck, Darmstadt, Germany). The tongue lesions derived from the 4NQO treatment were classified in oral leukoplakia and oral squamous cell carcinoma (OSCC), wherein the leukoplakia is considered an early phase of OSCC development (37). For oral leukoplakia diagnosis were considered the microscopic features of atrophy of the epithelium, hyperplasia with or without hyperkeratosis, and epithelial dysplasia (38). According with World Health Organization (39) criteria, the epithelial dysplasia degree of the leukoplastic lesions was classified in mild, moderate or severe. In the OSCC specimens, histological grade of malignancy

was evaluated by two oral pathologists (by consensus) in accordance with Bryne's criteria (40), in which the histopathological features keratinization degree, nuclear pleomorphism, pattern of invasion and lymphoplasmocytic infiltrate are observed in the invasive front of tumors.

For measuring the tumor thickness, microscopic images of OSCC slides stained with H&E were captured on a specific microscope (DM4000B Leica, Wetzlar, Germany) equipped with a digital camera. The measurement was performed from the deepest point of tumor invasion to the surface of the ulcer or epithelium, which was obtained in microns using the Qwin Plus software (Leica Microsystem Imaging Solutions Ltd., Cambridge, UK).

6. Tumor volume and weight loss

The tumor volume was calculated using the anteroposterior, laterolateral and depth clinical invasion measurements, which were obtained in millimeters by a calibrated caliper. The final volume (in mm³) was calculated by multiplying the three values found. Body weight of each animal was recorded weekly. Initial (before starting treatment with 4NQO) and final (before the animals' euthanasia) body measurements were used to calculate the weight loss during carcinogenic induction.

7. Stress-related hormones concentrations in the microenvironment post-carcinogen

To assess whether the chemically induced carcinogenesis promotes changes of the stress-related hormones levels in the tongue microenvironment, the norepinephrine, corticosterone, ACTH and BDNF post-carcinogen levels

were analyzed in the OSCC and oral leukoplakia tissues. For measuring these stress-related hormones, the same immunoassay techniques described above (ELISA and Milliplex Multi-Analyte Profiling) were used.

8. Expression of tumor progression-related genes by RT-PCR

In order to assess the associations among mRNA expression levels of five genes involved in the OSCC progression (7-14) and the pre- and post-carcinogen stress-related hormones levels in the microenvironment, the OSCC samples were analyzed by RT-PCR technique. Total RNA was extracted using the trizol reagent. Then, RNA samples were suspended in 20 μ L of RNase free ultrapure water for subsequent synthesis of complementary DNA (cDNA). Thereafter, RNA quantity and quality were verified by spectrophotometry, and cDNA was synthesized with specific kit (High Capacity RNA to cDNA kit; Invitrogen Life Technologies) using 1 μ g of total RNA according to the manufacturer's recommendations. mRNA levels were measured by TaqMan™ system in the StepOne Real-Time PCR™ equipment (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's recommendations. The primers for IL-6 (Rn00569848_m1), MMP-2 (Rn01538170_m1), MMP-9 (Rn00579162_m1), VEGF (Rn01511601_m1) and CDKN2a-p16 (Rn00580664_m1) were analyzed. β -actin (Rn00562253_m1) gene was used as endogenous control. The reactions were performed with a 20 μ L final volume. Thermal cycling conditions followed all the manufacturer's recommendations. The expression levels of each gene in each sample were normalized to β -actin mRNA levels. mRNA Relative Quantity (RQ) for each target gene was calculated using the comparative C_T method.

9. Statistical analysis

Statistical Analysis System 9.2 (SAS Institute Inc., Cary, NC, USA), GraphPad Prism 6.01 (GraphPad Software Inc., San Diego, CA, USA), Epi Info 7 (Centers for Disease Control and Prevention, Atlanta, GA, USA) and RStudio, using R version 3.2.0 (Integrated Development for R. RStudio Inc., Boston, MA, USA) softwares were used to perform all statistical tests. Pre-carcinogen stress-related hormones data were submitted as independent variables to the simple linear regression and penalized regression analysis to predict OSCC occurrence. Then, the clinicopathological and gene expression data were entered into the penalized regression model as response variables using the R function 'glmnet'. The objective of the penalized regression is to reduce the number of covariates by taking into account their correlation, which avoid a large variability in the β 's coefficient as well as reducing the number of predictors. The LASSO penalty was used in this analysis. Student's *t*-test was used to determine the differences between pre- and post-carcinogen hormones levels in the microenvironment. Furthermore, pre- and post-carcinogen stress hormones concentrations data were submitted to correlation analysis. Likewise, the same correlation test was used to evaluate associations among post-carcinogen hormones levels data and response variables. Level of statistical significance was set at a *p* value less than 0.05 for all statistical tests.

RESULTADOS

Results

1. Pre-carcinogen stress-related hormones concentrations in the tongue microenvironment are predictive for oral cancer occurrence.

After chemically induced oral carcinogenesis, 33 rats (68.75%) developed OSCC and 15 rats (31.25%) developed oral leukoplakias (Figure 4). All OSCCs were classified as well-differentiated tumors, according with the Bryne's criteria (40). Microscopic analysis showed that 80% of oral leukoplakias were diagnosed with moderate and severe epithelial dysplasia.




Figure 4. Clinical and histopathological features of oral leukoplakia and OSCC developed after chemically induced carcinogenesis by 4NQO (original magnification - 100x). (A) Small irregular yellowish-white plates. (B) Hyperplastic epithelium with mild dysplasia and hyperkeratosis. (C) Large heterogeneous white plate. (D) Moderate epithelial dysplasia with mild chronic inflammatory infiltrate. (E) Ulcerative lesion surrounded by few white areas. (F) Well-differentiated OSCC with intense inflammatory infiltrate underlying to neoplastic area. (G) Extensive ulcerative lesion reaching half of the tongue. (H) Highly infiltrative well-differentiated OSCC.

Simple linear regression analysis was performed to investigate whether the pre-carcinogen stress hormones levels in the microenvironment were predictive for OSCC occurrence. Increased pre-carcinogen concentrations of norepinephrine (OSCC, 0.1319 ± 0.0127 pg/ μ g; oral leukoplakia, 0.0834 ± 0.0085 pg/ μ g; $p=0.023$) and BDNF (OSCC, 0.2670 ± 0.0458 pg/ μ g; oral leukoplakia, 0.0818 ± 0.0212 pg/ μ g; $p=0.021$) in the tongue microenvironment were positively correlated with OSCC occurrence (Figures 5A and 5D). Nevertheless, pre-carcinogen concentrations of corticosterone (OSCC, 5.518 ± 0.7416 pg/ μ g; oral leukoplakia, 5.029 ± 0.6357 pg/ μ g; $p=0.520$) and ACTH (OSCC, 0.0053 ± 0.0009 pg/ μ g; oral leukoplakia, 0.0032 ± 0.0005 pg/ μ g; $p=0.186$) were not associated with oral cancer occurrence (Figures 5B and 5C). Likewise, penalized regression analysis was performed to identify the most relevant stress-related hormones to predict OSCC occurrence (Table I), and confirmed that higher pre-carcinogen norepinephrine concentrations were positively correlated with cancer occurrence ($p=0.025$). Increased pre-carcinogen BDNF concentrations were associated with a positive trend for oral cancer occurrence ($p=0.068$). Increased pre-carcinogen corticosterone concentrations were negatively correlated with OSCC occurrence ($p=0.039$).




Figure 5. Simple linear regression analysis among pre-carcinogen norepinephrine (A), corticosterone (B), ACTH (C) and BDNF (D) concentrations, and oral leukoplakia and OSCC occurrence. Pre-carcinogen norepinephrine and BDNF levels in the tongue microenvironment predicted oral cancer (* $p < 0.05$). Student's test- t between stress-related hormones levels means pre-carcinogenic induction, which were used to produce respective bar graphs; * $p < 0.05$.

Table I. Pre-carcinogen stress-related hormones in the tongue microenvironment and OSCC occurrence risk.

	Estimate	z Value	p Value
Norepinephrine	35.40	2.420	0.025*
Corticosterone	-0.63	-2.056	0.039*
ACTH	195.62	0.692	0.489
BDNF	10.53	1.775	0.068

*Values considered statistically significant at $p < 0.05$ (penalized regression analysis)

2. Pre-carcinogen stress-related hormones levels and their influences on the clinicopathological variables and tumor progression-related genes expression

Penalized regression analysis was conducted to elucidate the influence of pre-carcinogen stress-related hormones levels in the tongue microenvironment on the clinicopathological variables and mRNA levels for tumor progression-related genes (Table II) in OSCCs.

Clinicopathological variables. None of the pre-carcinogen hormones levels was correlated with clinicopathological variable such as tumor volume and thickness, and weight loss in rats who developed OSCC ($p > 0.05$). Likewise, the OSCC histopathological features, such as keratinization degree, nuclear pleomorphism, pattern of invasion and lymphoplasmocytic infiltrate were not correlated with the pre-carcinogen concentrations of these stress hormones in the microenvironment ($p > 0.05$). In the rats who developed oral leukoplakia, none of the hormones was correlated with epithelial dysplasia degree ($p > 0.05$).

Gene expression features in OSCC. Increased concentrations of pre-carcinogen norepinephrine were predictive for reduced CDKN2a-p16 mRNA levels in the OSCC tissue ($p = 0.0280$). However, the expressions of VEGF, MMP-2, MMP-9

and IL-6 were not correlated with the pre-carcinogen concentrations of stress hormones in the microenvironment ($p>0.05$).

Table II. Associations among pre-carcinogen stress-related hormones and clinicopathological variables and molecular features.

Variables	Norepinephrine			Corticosterone			ACTH			BDNF		
	Estimate	t Value	p Value	Estimate	t Value	p Value	Estimate	t Value	p Value	Estimate	t Value	p Value
Clinicopathological												
Tumor volume	1022.72	0.774	0.446	-21.35	-0.543	0.592	49587.91	1.415	0.169	-8.49	-0.017	0.986
Tumor thickness	7952.0	1.185	0.246	-180.47	-0.909	0.366	27559.27	1.559	0.131	-96.85	-0.039	0.969
Weight loss	-107.80	-0.647	0.521	-4.44	-0.997	0.325	1012.57	0.250	0.804	44.21	0.723	0.474
Keratinization degree	0.91	0.552	0.585	0.05	1.211	0.236	-42.77	-0.961	0.345	0.36	0.594	0.558
Nuclear pleomorphism	-8.90	-0.364	0.716	-1.16	-1.209	0.227	288.29	0.567	0.571	-10.08	-1.107	0.268
Pattern of invasion	-1.95	-0.487	0.630	-0.26	-1.890	0.069	105.30	1.186	0.245	0.82	0.802	0.429
Lymphoplasmocytic infiltrate	-16.47	-1.763	0.077	0.49	1.826	0.067	-348.29	-1.496	0.134	-0.42	-0.184	0.853
mRNA expression												
VEGF	-75.96	-1.450	0.168	2.05	1.218	0.242	-715.31	-0.390	0.702	-0.44	-0.030	0.976
MMP-2	-31.85	-1.706	0.109	0.73	1.231	0.237	-76.20	-0.117	0.909	2.02	0.385	0.705
MMP-9	-48.04	-0.305	0.765	2.43	0.481	0.638	-1567.41	-0.284	0.780	-7.24	-0.163	0.873
IL-6	-37.63	-0.385	0.706	-0.71	-0.221	0.828	-359.66	-0.102	0.920	3.44	0.145	0.887
CDKN2a-p16	-12.74	-2.420	0.028*	0.27	1.608	0.128	142.86	0.775	0.450	2.63	1.775	0.096

*Value considered statistically significant at $p < 0.05$ (penalized regression analysis)

3. Differences between pre- and post-carcinogen stress-related hormones concentrations in the microenvironment

The modulation of stress-related hormones levels induced by 4NQO carcinogen treatment was evaluated in the microenvironment. For this, student's *t*-test was performed to identify differences between pre- and post-carcinogen stress-related hormones concentrations. Post-carcinogen corticosterone levels in OSCC (32.752 ± 7.558 pg/ μ g) and oral leukoplakia (19.259 ± 4.246 pg/ μ g) were higher than hormone levels found in the normal tongue microenvironment before carcinogenic induction (OSCC, 5.518 ± 0.401 pg/ μ g; oral leukoplakia, 5.028 ± 0.635 pg/ μ g) ($p < 0.01$) (Figure 6B). Likewise, higher BDNF concentrations were found in the leukoplastic lesions post-carcinogen treatment (0.240 ± 0.037 pg/ μ g) compared to normal tissue pre-carcinogen treatment (0.093 ± 0.023 pg/ μ g) ($p = 0.008$). Nevertheless, no significant differences were found between pre-carcinogen BDNF levels in the normal tissue (0.266 ± 0.045 pg/ μ g) and OSCC tissue (0.238 ± 0.019 pg/ μ g) ($p = 0.653$) (Figure 6D). No differences were found between pre- and post-carcinogen norepinephrine (Figure 6A) and ACTH (Figure 6C) concentrations for OSCC and leukoplastic lesions ($p > 0.05$). There were no differences regarding stress-related hormones concentrations between OSCC and oral leukoplakia ($p > 0.05$) (Figure 6). When all hormonal data from oral leukoplakia and OSCC were analyzed together, pre-carcinogen ACTH levels in the tongue microenvironment were higher than post-carcinogen hormone levels ($p = 0.014$) (data were not shown) indicating that differently from observed with corticosterone, ACTH levels in microenvironment decrease after carcinogen treatment.

Pre-carcinogen stress-related hormones levels were positively correlated to each other ($p < 0.001$; Figures 7A, 7C, 7E, 7G, 7I and 7K). However, when the correlations among the stress hormones concentrations were analyzed in post-carcinogen period the only positive associations that were preserved were ACTH with each one of other three hormones studied ($p < 0.05$; Figure 7D, 7H and 7L). Thus, these results indicate a misbalance in stress-related hormones secretion into microenvironment during carcinogenesis induction.




Figure 6. Student's test-*t* between pre- and post-carcinogen levels of norepinephrine (A), corticosterone (B), ACTH (C) and BDNF (D). Increased post-carcinogen corticosterone concentrations were found in the tumor and leukoplastic lesions (* $p < 0.05$). Higher post-carcinogen BDNF levels were found only in the leukoplastic lesions compared to pre-carcinogen normal mucosa; * $p < 0.05$.




Figure 7. Correlation analysis showing a positive correlation between pre-carcinogen stress-related hormones levels (A, C, E, G, I and K; $*p<0.001$). A positive correlation was also observed in the post-carcinogen concentrations of norepinephrine vs ACTH (D; $*p<0.001$), corticosterone vs ACTH (H; $*p=0.035$) and ACTH vs BDNF (L; $*p<0.001$).

4. Associations among post-carcinogen stress-related hormones levels in the OSCC microenvironment and clinicopathological and molecular variables

When clinicopathological variables from OSCCs were correlated with post-carcinogen stress-related hormones, higher norepinephrine concentrations were associated to increased tumor volume ($p < 0.001$). Likewise, an increase in the tumor thickness was correlated with higher norepinephrine levels in OSCC microenvironment ($p = 0.003$). Weight loss of the animals with OSCC during carcinogenesis period was not associated to the post-carcinogen stress-related hormones concentrations ($p > 0.05$). In addition, the OSCCs microscopic features keratinization degree, nuclear pleomorphism and pattern of invasion were not associated with the hormones levels in the tumor microenvironment ($p > 0.05$). Higher levels of norepinephrine ($p = 0.015$), ACTH ($p = 0.015$) and BDNF ($p = 0.019$) were associated with a lesser intensity of the lymphoplasmocytic infiltrate underlying to tumor. In the rats who developed oral leukoplakia, post-carcinogen stress-related hormones levels were not associated to epithelial dysplasia degree ($p > 0.05$). The associations among post-carcinogen stress-related hormones levels and clinicopathological features are shown in Table III. The VEGF, MMP-2, MMP-9 and CDKN2a-p16 expressions in OSCC microenvironment were not associated to stress hormones concentrations ($p > 0.05$). However, IL-6 gene overexpression was associated with increased levels of corticosterone in the tumor tissue ($p < 0.001$).

Table III. Associations among post-carcinogen stress-related hormones and clinicopathological variables and molecular features.

Variables	Norepinephrine			Corticosterone			ACTH			BDNF		
	R	R ²	p Value	R	R ²	p Value	R	R ²	p Value	R	R ²	p Value
Clinicopathological												
Tumor volume	0.852	0.7259	<0.001*	-0.060	0.0036	0.793	-0.064	0.0040	0.780	-0.096	0.0092	0.686
Tumor thickness	0.726	0.5270	0.003*	-0.039	0.0015	0.866	-0.063	0.0039	0.784	-0.080	0.0064	0.736
Weight loss	-0.073	0.0053	0.742	-0.294	0.0864	0.114	0.064	0.0040	0.534	0.092	0.0084	0.434
Keratinization degree	-0.056	0.0031	0.807	0.144	0.0207	0.544	0.049	0.0024	0.834	0.048	0.0023	0.842
Nuclear pleomorphism	-0.060	0.0036	0.793	0.195	0.0380	0.408	-0.115	0.0132	0.627	-0.110	0.0121	0.651
Pattern of invasion	-0.092	0.0084	0.690	-0.030	0.0009	0.900	-0.117	0.0136	0.621	-0.121	0.0146	0.621
Lymphoplasmocytic infiltrate	-0.437	0.1909	0.015*	-0.313	0.0979	0.178	-0.531	0.2819	0.015*	-0.529	0.2798	0.019*
mRNA expression												
VEGF	-0.220	0.0484	0.336	0.063	0.0039	0.785	-0.042	0.0017	0.855	-0.052	0.0027	0.824
MMP-2	-0.201	0.0404	0.381	0.270	0.0729	0.236	0.020	0.0004	0.930	0.022	0.0004	0.923
MMP-9	-0.063	0.0039	0.783	0.199	0.0396	0.386	-0.014	<0.0001	0.951	0.058	0.0033	0.808
IL-6	-0.033	0.0010	0.887	0.817	0.6674	<0.001*	-0.001	<0.0001	0.994	-0.037	0.0013	0.877
CDKN2a-p16	-0.094	0.0088	0.682	0.009	<0.0001	0.968	0.105	0.0110	0.647	0.090	0.0081	0.703

*Values considered statistically significant at p<0.05 (correlation analysis)

DISCUSSÃO

Discussion

A long time it has been speculated that stress-related hormones could influence the cancer progression and onset. Although studies increasingly solidifies understanding that stress can relevantly affect tumor progression (1-4), its influence on the cancer occurrence is poorly understood. In this context, what still more obscure is the role of stress-related hormones as co-factors in conjunction with carcinogenic substances on the cancer induction. Although recent findings on stress hormones action in tissue microenvironment be increasingly understood for malignant phenotype induction (22,23,41), until the moment there were no investigations that have evaluated if baseline (pre-carcinogen) levels of the stress-related hormones in the microenvironment would have predictive value for cancer development and progression. In the present study, we have used a classic model of chemically induced carcinogenesis (36) to evaluate the influence of stress-related hormones on the oral malignancies occurrence. Our results demonstrated the first *in vivo* evidence that pre-carcinogen concentrations of norepinephrine and BDNF and reduced pre-carcinogen corticosterone levels were predictive for oral cancer occurrence, although the BDNF results have not reach statistical significance in penalized regression analysis.

In our findings, animals who had increased norepinephrine concentrations in the pre-carcinogen tongue microenvironment have had about 35 times higher chance of developing tongue carcinomas. Investigations have showed that norepinephrine can induce significant alterations in molecular pathways of the

carcinogenesis process (14,41-44). A study involving a chronic stress model showed that norepinephrine and epinephrine act via both Gs-protein kinase A (PKA) and β -arrestin-mediated signaling pathways inducing DNA damage and suppressing p53 concentrations through the AKT-mediated activation of MDM2 (41), which may increase considerably the cellular tumorigenicity. Activated-norepinephrine receptors (beta-adrenergic signaling) can trigger other oncogenic intracellular processes, such as the increase of cyclic AMP (cAMP) levels (14), and RAS signaling pathway (42) and transcriptional factor Stat 3 hyperactivation (43). According to Fitzgerald (44), higher norepinephrine levels could stimulate its extracellular receptors increasing the chances of developing cancer. Likewise, it has also been shown that chronic exposure to norepinephrine causes an increase in DNA-damage in 3T3 mouse fibroblasts (22). Interestingly, pre-clinical studies using chemically induced carcinogenesis models have showed that drug administration or low protein diet consumption in stomach (45,46), colon (47,48) and liver (49) were directly associated with an increase of carcinogenesis in these tissues and these events were associated to increased norepinephrine levels in tumor microenvironment. The *in vivo* results of this study indicate that not stress-induced basal increased norepinephrine concentrations in the microenvironment may be an important factor to act in conjunction with carcinogenic substances in the activation of oncogenic signaling pathways.

Higher pre-carcinogen corticosterone concentrations found in the pre-carcinogen tongue microenvironment were negatively correlated with OSCC occurrence in penalized regression analysis. In a way, this data was unexpected. In our initial hypothesis, data regarding corticosterone levels influence on

carcinogenesis should be positively correlated to norepinephrine findings with higher hormonal levels predicting tumor occurrence. Pyter & Prendergast (51) found that plasma corticosterone levels before carcinogen treatment predicted mammary cancer onset. In the present study, we have not evaluated the pre-carcinogen systemic hormonal concentrations in order to compare them to tissue microenvironment levels and evaluate impact on OSCC occurrence. Anyway, some evidences can support the corticosterone-related effects on carcinogenesis observed in our experiment. In female rats, per example, dietary administration of corticosterone has influenced a dose-dependent reduction in the incidence, multiplicity and size of mammary carcinomas (51). Under hepatocarcinogenesis induction, corticosterone injections inhibited precancerous cells growth and increased specific survival in another pre-clinical study (52). In a mouse model, topical dexamethasone treatment promoted an inhibition of skin carcinogenesis (53). Furthermore, glucocorticoid-mediated COX-2 inhibition promoted 11 β -hydroxysteroid dehydrogenase type II (11 β HSD2) inhibition in human lung cancer cells; *in vivo*, 11 β HSD2 inhibition decreased lung tumor growth and invasion, and was associated with higher tissue glucocorticoids levels (54). Further investigations are necessary to confirm the different modulation in the same pre-carcinogen microenvironment promoted by the norepinephrine and corticosterone on carcinogenesis like found in this study. Pre-carcinogen ACTH concentrations in tongue microenvironment, differently of norepinephrine and corticosterone, were not predictive for oral cancer occurrence.

Increased pre-carcinogen BDNF levels in the tongue microenvironment were positively correlated with OSCC development in the simple linear regression

analysis and showed a positive trend to significance in the penalized regression analysis. BDNF levels are increased in response to stress (25,26) and may activate the TrkB receptors of PC12 cells in the rodents' adrenal medulla, which can release norepinephrine and epinephrine into the bloodstream (25). BDNF is overexpressed in more than a half of human head and neck squamous cell carcinomas and can induce cellular migration and tumor invasion through of TrkB activation, which could be a critical component for tumor progression (27). Likewise, oncogenic signaling pathways are activated by the BDNF, such as the upregulation of the phosphoinositide-3 kinase AKT-cascade (55) and MAPK p42/44 phosphorylation (56), resulting in cAMP activation (55,56). In addition, TrkB overexpression results in an altered expression of E-cadherin (with downregulation, in epithelium) and Twist (with upregulation, in mesenchyme) in the microenvironment (27). Interestingly, Twist transcriptional activity in stroma through AKT activation induces severe alterations in the epithelial cells (57). Although the predictive influence of pre-carcinogen BDNF concentrations in the tongue microenvironment for OSCC occurrence has not reached statistical significance, the present study data might suggest a specific role of this biomarker in carcinogenesis.

Although norepinephrine has been predicted for oral cancer occurrence, none of the pre-carcinogen hormones in the tongue microenvironment has influenced the post-carcinogen clinicopathological variables, such as tumor volume and thickness or keratinization degree and nuclear pleomorphism. Nevertheless, higher pre-carcinogen norepinephrine levels were predictive for CDKN2a-p16 mRNA lower expression in the tumor microenvironment. CDKN2a-

p16 is an important tumor-suppressor gene and its alteration is a frequent event in the tongue OSCC development in humans (58). This gene encodes the p16 protein, which has the ability to inhibit the activity of the CDK-4 and CDK-6 (cyclin D complex) that are necessary for phosphorylation of retinoblastoma protein and the G1-S phase transition of cell cycle progression (58,59). In the human tumors, CDKN2a-p16 gene inactivation during carcinogenesis process is caused by the homozygous deletions, inactivating mutations and promoter hypermethylation and is associated with loss of p16 protein expression (59). By the first time, stress hormone norepinephrine has been linked to CDKN2a-p16 lower expression in the tumor microenvironment, which could have a role in oncogenic signaling pathways activation. On the other hand, Schraml et al. (60) demonstrated that p16 is transcriptionally activated in murine hematopoietic progenitor cells after treatment with alpha- (oxymetazoline) and beta-adrenergic (terbutaline sulfate) agonists.

For better understanding of stress-related hormones levels modulation in the microenvironment derived from chemically induced oral carcinogenesis, pre-carcinogen hormones concentrations were compared to post-carcinogen levels. Interestingly, the results demonstrated that treatment with 4NQO carcinogen increased the corticosterone concentrations in the oral leukoplakia and OSCC microenvironment compared to normal mucosa before carcinogen treatment. BDNF concentrations were also higher in the oral leukoplakia microenvironment than pre-carcinogen normal mucosa. A possible explanation for these features is that chronic exposure to the chemical carcinogen can lead to a dysregulated production and release of these stress-related hormones by the epithelial and mesenchymal cells in the tissue microenvironment during tumor induction. The

substantial increase of the corticosterone levels in oral leukoplakia and OSCC microenvironments were probably related to an increased cellular endocrine reactivity due to stimulus-stressor of the carcinogen. An investigation showed that persistent activation of HPA axis in melanoma cells is caused by UV radiation resulting in the production of glucocorticoids (34). Likewise, HPA axis could be hyperactivated in oral cancer cells in response to 4NQO carcinogen. When the ACTH post-carcinogen levels in oral leukoplakia and OSCC tissues were evaluated in conjunction, the levels of this hormone were reduced after carcinogen treatment, an opposite result to that observed with corticosterone. Thus, higher systemic and local post-carcinogen corticosterone concentrations could be inhibiting the ACTH production by the tumor microenvironment cells (negative feedback effect). In another study, Al-Wadei et al. (33) using pancreatic cancer cell lines and immortalized human pancreatic duct epithelial cell line demonstrated that these cell lines produced and released norepinephrine and epinephrine upon exposure to nicotine (a chemical carcinogen), and this mechanism was mediated by the nicotinic acetylcholine receptors. In this study, despite the carcinogenic induction has increased the norepinephrine levels, this result has not reach statistical significance.

Higher post-carcinogen norepinephrine levels in OSCC microenvironment were correlated with greater tumor volume and thickness, suggesting its involvement in oral cancer progression *in vivo*. A pre-clinical study in nude mice showed a positive correlation among chronic stress and increased plasma concentrations of catecholamines and glucocorticoid, greater tumor size, and more invasive growth of human oral carcinoma cells (61). Sood et al. (12) showed

that stress levels of norepinephrine and epinephrine increased the invasiveness of ovarian cancer cells lines. Likewise, under chronic stress, increased catecholamines concentrations induced tumor growth of ovarian carcinoma and angiogenesis in an orthotopic mouse model through the activation of cAMP-PKA by the β_2 adrenergic receptor, with an overexpression of VEGF, MMP-2 and MMP-9 (8). Similarly, norepinephrine treatment increased invasiveness, VEGF, MMP-2 and MMP-9 levels in culture supernatants of nasopharyngeal carcinoma (14) and OSCC cells proliferation (11) in a dose-dependent response, and these effects were blocked by propranolol (a beta-blocker). Higher corticosterone concentrations in the tumor microenvironment were associated to enhanced IL-6 mRNA levels. Bernabé et al. (11) showed that cortisol stress levels tended to increase IL-6 expression in a human OSCC cell line. Another investigation showed that norepinephrine increased expression of IL-6 mRNA and protein levels in human ovarian carcinomas cells through Src tyrosine kinase-dependent mechanism (10).

Studies have shown that increased concentrations of the stress-related hormones induce lymphocytes apoptosis and impair the macrophages functions (1,62). Catecholamines and glucocorticoids inhibit IL-12 production by the antigen-presenting cells (monocytes, macrophages and dendritic cells), which promotes type 1 helper cells (Th1) response and cellular immunity (1,62). Therefore, the inhibition mechanism or selective suppression of the Th1 lymphocyte's functions impairs the cellular immune responses against some tumors (1). In the present study, increased post-carcinogen concentrations of norepinephrine, ACTH and BDNF were associated with a lesser intensity of the

lymphoplasmocytic infiltrate underlying to tumor, thereby suggesting a probable immunosuppressive effect of these stress-related hormones in the OSCC microenvironment, which could facilitate tumor advancement. ACTH hormone has been considered an immuno-regulator, which plays a central role in important immune responses, such as chemotaxis and phagocytosis (63), whereas BDNF can decrease the levels of NK cells (64). Although oral leukoplakia is classified as a potentially malignant disorder or even an intermediate process of OSCC development (37), pre- and post-carcinogen stress-related hormones levels were not associated to epithelial dysplasia degree. The small size of oral leukoplakia sample may have influenced in obtaining these negative results.

The present study is original in its purpose and methodology. This is the first time that a classic chemically induced carcinogenesis pre-clinical model has been used to test the hypothesis by which individual variability of basal hormonal levels in the tongue microenvironment could act in conjunction with carcinogen predisposing cancer development. In humans, the conduction of cohort prospective studies that allow to evaluate the influence of local and systemic stress-related hormones on cancer onset is not simple. Although it is an excellent resource for studying the influence of stress hormones on the carcinogenesis process, the collection of biological samples before cancer development from human normal tissues requires a large population sample and its follow up until the cancer occurrence. In this study, we had success in reproducing this methodological perspective in animals, in order to study the presence of stress-related hormones in the normal tissue microenvironment, which would be induced to cancer some time later. This methodology provides perspectives of its

use for the investigation of physiological and genetic individual alterations in the microenvironment and their effects on oral carcinogenesis.

Although pre-carcinogen stress-related hormones levels in the tongue microenvironment have been predicted for OSCC occurrence and progression, behavior tests were not performed for analyzing the rats' stress levels. Likewise, the systemic hormonal levels were not evaluated, which would be interesting for crossing them with the tongue microenvironment concentrations. Moreover, we have explored the stress hormones levels in the microenvironment, but not their receptor-dependent action. The hormonal biological effects are directly dependent on the biochemistry affinity between the hormones and receptors. Thus, future experiments that block or potentiate the action of beta-adrenergic, glucocorticoid and TrkB receptors may expand the understanding of their agonists' role on the chemically induced carcinogenesis process.

The first evidences that basal pre-carcinogen stress-related hormones levels in the microenvironment in natural conditions may predict chemically induced cancer occurrence were shown in the present investigation. Increased norepinephrine levels (related inversely to corticosterone levels) in the tongue microenvironment before oral carcinogenesis induction were predictive for tumor occurrence. Likewise, BDNF proved to be a promising biomarker for oral cancer occurrence. Furthermore, carcinogen may act as a potent exogenous stressor increasing stress hormones levels in the microenvironment, which can affect cancer progression. Although they have been observed in a pre-clinical model, the results of the present investigation strongly suggest that endocrine individual differences in the tissue microenvironment before carcinogen exposure can be

related to a higher susceptibility to tumor development in chemically induced carcinogenesis.

REFERÊNCIAS

References[†]

1. Reiche, E.M. et al. (2004) Stress, depression, the immune system, and cancer. *Lancet Oncol.*; 5(10): 617-25.
2. Thaker, P.H. et al. (2007) The neuroendocrine impact of chronic stress on cancer. *Cell Cycle.*; 6(4): 430-3.
3. Antoni, M.H. et al. (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. *Nat Rev Cancer.*; 6(3): 240-8.
4. Lutgendorf, S.K. et al. (2011) Biobehavioral factors and cancer progression: physiological pathways and mechanisms. *Psychosom Med.*; 73(9): 724-30.
5. Smith, S.M. et al. (2006) The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. *Dialogues in Clinical Neuroscience.*; 8(4): 383-395.
6. McCorry, L.K. (2007) Physiology of the Autonomic Nervous System. *American Journal of Pharmaceutical Education.*; 71(4): 78.
7. Lutgendorf, S.K. et al. (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. *Clin Cancer Res.*; 9(12): 4514-21.
8. Thaker, P.H. et al. (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nat Med.*; 12(8): 939-44.
9. Lutgendorf, S.K. et al. (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. *J Clin Oncol.*; 26(29): 4820-7.

[†]Normalização segundo o periódico “Carcinogenesis” (Anexo B)

10. Nilsson, M.B. et al. (2007) Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. *J Biol Chem.*; 282(41): 29919-26.
11. Bernabé, D.G. et al. (2011) Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. *Brain Behav Immun.*; 25(3): 574-83.
12. Sood, A.K. et al. (2006) Stress hormone-mediated invasion of ovarian cancer cells. *Clin Cancer Res.*; 12(2): 369-75.
13. Lutgendorf, S.K. et al. (2008) Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. *Clin Cancer Res.*; 14(21): 6839-46.
14. Yang, E.V. et al. (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. *Cancer Res.*; 66(21): 10357-64.
15. Inbar, S. et al. (2011) Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity. *PLOS One.*; 6(4): e19246.
16. Chang, M. et al. (2005) Beta-adrenoreceptors reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via PKA-dependent control of viral RTA. *J Virol*; 79: 13538-47.
17. Ben-Eliyahu, S. et al. (1991) Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. *Brain Behav Immun.*; 5(2): 193-205.

18. Melamed, R. et al. (2005) Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. *Brain Behav Immun.*; 19(2): 114-26.
19. Lointier, P. et al. (1992) The effects of steroid hormones on a human colon cancer cell line in vitro. *Anticancer Res.*; 12(4): 1327-30.
20. Rich, T. et al. (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. *Clin Cancer Res.*; 11(5): 1757-64.
21. Bernabé, D.G. et al. (2012) Increased plasma and salivary cortisol levels in patients with oral cancer and their association with clinical stage. *J Clin Pathol.*; 65(10): 934-9.
22. Flint, M.S. et al. (2013) Chronic exposure to stress hormones promotes transformation and tumorigenicity of 3T3 mouse fibroblasts. *Stress.*; 16(1): 114-21.
23. Feng, Z. et al. (2012) Chronic restraint stress attenuates p53 function and promotes tumorigenesis. *Proc Natl Acad Sci U S A.*; 109(18): 7013-8.
24. Lewin, G.R. et al. (1996) Physiology of the neurotrophins. *Annu Rev Neurosci.*; 19: 289-317.
25. Tsukinoki, K. et al. (2012) Role of stress-related brain-derived neurotrophic factor (BDNF) in the rat submandibular gland. *Acta Histochem Cytochem.*; 45(5): 261-7.
26. Saruta, J. et al. (2010) Chronic stress affects the expression of brain-derived neurotrophic factor in rat salivary glands. *Stress.*; 13(1): 53-60.

27. Kupferman, M.E. et al. (2010) TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. *Oncogene.*; 29(14): 2047-59.
28. Yang, Z.F. et al. (2005) Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. *Cancer Res.*; 65(1): 219-25.
29. Bronzetti E. et al. (2008) A possible role of BDNF in prostate cancer detection. *Oncol Rep.*; 19(4): 969-74.
30. Lai, P.C. et al. (2010) Overexpression of BDNF and TrkB in human bladder cancer specimens. *Oncol Rep.*; 24(5): 1265-70.
31. Hu, M. et al. (2008) Microenvironmental regulation of cancer development. *Curr Opin Genet Dev.*; 18(1): 27-34.
32. Bhowmick, N.A. et al. (2005) Tumor-stroma interactions. *Curr Opin Genet Dev.*; 15(1): 97-101.
33. Al-Wadei, M.H. et al. (2012) Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors $\alpha 3$, $\alpha 5$, and $\alpha 7$. *Mol Cancer Res.*; 10(2): 239-49.
34. Brozyna, A. et al. (2007) Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma. *Expert review of dermatology.*; 2(4): 451-469.
35. Lowry, O.H. et al. (1951) Protein measurement with the folin phenol reagent. *J Biol Chem.*; 193(1): 265-75.
36. Ribeiro, D.A. et al. (2004) Genomic instability in non-neoplastic oral mucosa cells can predict risk during 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. *Oral Oncol.*; 40(9): 910-5.

37. Warnakulasuriya, S. et al. (2007) Nomenclature and classification of potentially malignant disorders of the oral mucosa. *J Oral Pathol Med.*; 36(10): 575-80.
38. van der Waal, I. et al. (1997) Oral leukoplakia: a clinicopathological review. *Oral Oncol.*; 33(5): 291-301.
39. Barnes, L. et al. (2005) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC Press.
40. Byrne, M. (1998) Is the invasive front of an oral carcinoma the most important area for prognostication? *Oral Dis.*; (2): 70-7.
41. Hara, M.R. et al. (2011) A stress response pathway regulates DNA damage through β 2-adrenoreceptors and β -arrestin-1. *Nature.*; 477 (7364): 349-53.
42. Muthalif, M.M. et al. (1998) 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. *Proc Natl Acad Sci USA.*; 95(21): 12701-6.
43. Landen, C.N.Jr. et al. (2007) Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. *Cancer Res.*; 67(21): 10389-96.
44. Fitzgerald, P.J. (2009) Is norepinephrine an etiological factor in some types of cancer? *Int J Cancer.*; 124(2): 257-63.
45. Tatsuta, M. et al. (1998) Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. *Int J Cancer.*; 77(3): 467-9.

46. Tatsuta, M. et al. (1991) Enhanced induction of gastric carcinogenesis by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats fed a low-protein diet. *Cancer Res.*; 51(13): 3493-6.
47. Iishi, H. et al. (1993) Enhancement by the tricyclic antidepressant, desipramine, of experimental carcinogenesis in rat colon induced by azoxymethane. *Carcinogenesis*.; 14(9): 1837-40.
48. Tatsuta, M. et al. (1992) Enhanced induction of colon carcinogenesis by azoxymethane in Wistar rats fed a low-protein diet. *Int J Cancer*.; 50(1): 108-11.
49. Tatsuta, M. et al. (1989) Inhibition by cysteamine of hepato- carcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. *Int J Cancer*.; 44(3): 529-33.
50. Pyter, L.M. et al. (2013) Individual differences in pre-carcinogen cytokine and corticosterone concentrations and depressive-like behavior predict tumor onset in rats exposed to a carcinogen. *Psychoneuroendocrinology*.; 38(6): 800-7.
51. Zhu, Z. et al. (2003) Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas. *Carcinogenesis*.; 24(7): 1225-31.
52. Bouzahzah, B. et al. (1998) The role of corticoids, adrenalectomy, phenobarbital and pentobarbital in the promotion of DEN-hepatocarcinogenesis. *In Vivo*.; 12(4): 411-9.
53. Strawhecker, J.M. et al. (1992) Inhibition of mouse skin tumorigenesis by dexamethasone occurs through a Ha-ras-independent mechanism. *Carcinogenesis*.; 13(11): 2075-80.

54. Chang, J. et al. (2015) Inhibition of 11 β -Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression as Well as the ERK and mTOR Signaling Pathways. *PLOS One.*; 10(5): e0127030.
55. Chao, M.V. et al. (2004) Neurotrophin survival signaling mechanisms. *J Alzheimers Dis.*; 6(6 Suppl): S7-11.
56. Li, Z. et al. (2007) Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. *Cell Death Differ.*; 14(2): 318-26.
57. Smit, M.A. et al. (2009) A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. *Mol Cell Biol.*; 29(13): 3722-37.
58. Lim, A.M. et al. (2014) Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. *Int J Cancer.*; 135(4): 887-95.
59. Liggett, W.H. Jr. et al. (1998) Role of the p16 tumor suppressor gene in cancer. *J Clin Oncol.*; 16(3): 1197-206.
60. Schraml, E. et al. (2009) Acute adrenergic stress inhibits proliferation of murine hematopoietic progenitor cells via p38/MAPK signaling. *Stem Cells Dev.*; 18(2): 215-27.
61. Xie, H. et al. (2015) Chronic stress promotes oral cancer growth and angiogenesis with increased circulating catecholamine and glucocorticoid levels in a mouse model. *Oral Oncol.*; 51(11): 991-7.
62. Moynihan, J.A. (2003) Mechanisms of stress-induced modulation of immunity. *Brain Behav Immun.*; 17 Suppl 1: S11-6.

63. Ottaviani, E. et al. (1999) ACTH and its role in immune-neuroendocrine functions. A comparative study. *Curr Pharm Des.*; 5(9): 673-81.
64. Yu, X. et al. (2016) Brain-derived neurotrophic factor modulates immune reaction in mice with peripheral nerve xenotransplantation. *Neuropsychiatric disease and treatment.*, 12: 685.

ANEXO A

ANEXO A - Certificado da Comissão de Ética no Uso de Animais (CEUA).



UNIVERSIDADE ESTADUAL PAULISTA
"JÚLIO DE MESQUITA FILHO"



CAMPUS ARAÇATUBA
FACULDADE DE ODONTOLOGIA
FACULDADE DE MEDICINA VETERINÁRIA

CEUA - Comissão de Ética no Uso de Animais
CEUA - Ethics Committee on the Use of Animals

CERTIFICADO

Certificamos que o Projeto de Pesquisa intitulado **"Variabilidade individual da atividade do sistema nervoso simpático e análise de sua influência sobre a carcinogênese bucal induzida por 4-NQO"**, Processo FOA nº 2014-00816, sob responsabilidade de Daniel Galera Bernabé apresenta um protocolo experimental de acordo com os Princípios Éticos da Experimentação Animal e sua execução foi aprovada pela CEUA em 02 de Setembro de 2014.

VALIDADE DESTE CERTIFICADO: 31 de Julho de 2016.


DATA DA SUBMISSÃO DO RELATÓRIO FINAL: até 30 de Agosto de 2016.

CERTIFICATE

We certify that the study entitled **"Individual variability of sympathetic nervous system activity and analysis of its influence on the 4-nitroquinoline 1-oxide-induced oral carcinogenesis"**, Protocol FOA nº 2014-00816, under the supervision of Daniel Galera Bernabé presents an experimental protocol in accordance with the Ethical Principles of Animal Experimentation and its implementation was approved by CEUA on September 02, 2014.

VALIDITY OF THIS CERTIFICATE: July 31, 2016.

DATE OF SUBMISSION OF THE FINAL REPORT: August 30, 2016.


Prof. Dra. Maria Gisela Laranjeira
Coordenadora da CEUA
CEUA Coordinator

ANEXO B

ANEXO F - Normas para publicação no periódico “Carcinogenesis”.**Preparation of manuscripts**

Manuscripts should be in their final form when they are submitted so that proofs will require only correction of typographical errors. Manuscripts must be submitted according to the manuscript template, available online here. A mini-style checklist is also available online here.

Sections of the manuscript

Regular full-length papers should be subdivided into the following sequence of sections: Title page, Abstract, Introduction, Materials and methods, Results, Discussion, Acknowledgements, References, Tables and Legends to Figures. In the journal the Materials and methods, Acknowledgements and References will be printed in smaller type to accommodate more text.

Authors should follow the below guidelines for manuscript length:

5000 words (excluding references and figure legends)

6 or fewer tables and/or figures (6 in total)

250 word limit for the abstract

50 references

In addition to the abstract, manuscripts should also a 40-word summary of the article's main point. This may be used to highlight the article in the contents list online and in e-mail alerts. Such a summary is not compulsory, but is likely to encourage readers browsing the table of contents to read your article.

Supplementary Material Only directly relevant material should be included in the full text of manuscripts. Supporting materials, which are not essential in the full text, but would nevertheless benefit the reader, can be published as online-only supplementary data. Supplementary data should be submitted for review, in a separate file from the manuscript. Authors should ensure that supplementary data is referred to in the main manuscript at an appropriate point in the text.

Language editing

Particularly if English is not your first language, before submitting your manuscript you may wish to have it edited for language. This is not a mandatory step, but may help to ensure that the academic content of your paper is fully understood by journal editors and/or reviewers. Language editing does not guarantee that your manuscript will be accepted for publication. If you would like information about one such service please [click here](#). There are other specialist language editing companies that offer similar services and you can also use any of these. Authors are liable for all costs associated with such services.

General format

As referees may choose to print out your paper for reviewing purposes, all sections of the manuscript must be double-spaced with margins of 25mm (one

inch) left at the sides, top and bottom of each page. Number each page top right (Title Page is 1). Please avoid footnotes, use instead, and as sparingly as possible, parenthesis within brackets.

Abstract

The second page of every manuscript must contain only the Abstract, which should be a single paragraph not exceeding 250 words. Published papers will only have the first 250 words of their abstracts incorporated into Medline, text in excess of this limit will be lost. The Abstract should be comprehensible to readers *before* they have read the paper, and abbreviations and reference citations should be avoided.

Acknowledgements

The acknowledgements should be included at the end of the text. Personal acknowledgements should precede those of institutions or agencies.

References

Authors are responsible for the accuracy of the References. Published articles and those in press (state the journal which has accepted them) may be included. Arrange references in numerical order with the numbers in the text in brackets and on the line (not as superscripts). In the reference list please note that for more than one author the first author name should be mentioned and the initials follow the name; then et al. The date should precede the title; the title should be given in full; the name of the journal should be abbreviated according

to the World List of Scientific Periodicals and underlined to indicate italics.

References should therefore be listed as follows:

1. Wilting, S. M. et al. (2010) Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. *Mol. Cancer*, 9, 167.
2. Hatch, F. Tet al (1984) Identification of mutagens from the cooking of food. In de Serres, F. J. (ed.) *Chemical Mutagens: Principles and Methods for their Detection*. Plenum Press, New York, vol. 9, pp. 111-164.
3. Rothman K. J. et al. (1998) *Modern Epidemiology*. Lippincott Williams and Wilkins, Philadelphia.

Personal communications should be authorized by those involved, in writing, and unpublished data should be cited as (unpublished data). Both should be used as sparingly as possible and only when the unpublished data referred to is peripheral rather than central to the discussion. References to manuscripts in preparation, or submitted but not yet accepted, should be cited in the text as (B. Smith and N. Jones, in preparation) and should NOT be included in the list of references.

Tables

Tables should be numbered consecutively with Roman numerals, they should be self-explanatory and include a brief descriptive title. Footnotes to tables indicated by lower case letters are acceptable, but they should not include extensive experimental detail. Please supply as rich text format or a word document not as a PowerPoint attachment.

Requirements for images

The Journal recommends, but does not require, authors to make available full blots as supplementary data - to avoid the risk of claims from readers in the future with respect to image manipulation. As with all data being reported, editors may request to review original data/images either during the review process or post-publication. Authors are advised of their responsibility to archive original data for a suitable time period after study closure.

Image manipulation beyond minimal processing (for instance, to add arrows to a micrograph) is strictly forbidden. All digitized images submitted with the final version of the manuscript must be of high quality and have resolutions of at least 300 d.p.i for colour, 600 d.p.i. for greyscale and for .eps format 1200 d.p.i. for line art.

Single images created from separately acquired (eg, different times or from different locations) are not permitted unless it is clearly stated in the legend that the combined image is, for example, time-averaged data or a time-lapse sequence. If comparative images are required in one figure then separate images must be demarcated in the whole figure and described in the legend.

Changing contrast or brightness may be acceptable when it is applied evenly over the whole image including over the controls. Reducing or increasing contrast to hide data is forbidden. Processing to emphasize a region in an image to the detriment of other regions is inappropriate, particularly where an attempt is made to reinforce significance of experimental data relative to the control.

Use of cloning and healing tools, such as those available in Photoshop, or any feature that deliberately obscures manipulations, is considered inappropriate. Where such tools are used by necessity, for example to remove identifying data about patients from an image, then this should be explicitly mentioned in the figure legend.

Electrophoretic gels and blots

Carcinogenesis allows cropped gels and blots, but cropping must be indicated in the image and mentioned in the figure legend. If a manuscript is accepted, the Journal recommends, but it is not compulsory, that full-length gels and/or blots are made available as supplementary data.

All gels must include positive and negative controls, as well as molecular size markers; where these are not visible in the cropped figure then such controls must show clearly in the expanded data supplementary figure.

Please provide a citation for characterized antibodies. Where a citation is not yet available, then a detailed characterization demonstrating the specificity of the antibody and the range of reactivity of the reagent in the assay, should be supplied as supplementary information.

Carcinogenesis recommends submission of data and linking with an antibody profile database (e.g., Antibodypedia, 1DegreeBio).

While Carcinogenesis discourages quantitative comparisons between samples on different gels/blots, if this is part of the experiment reported, then the

legend must state that the samples derive from the same experiment and that gels/blots were processed in parallel. Sliced images that compare lanes that were non-adjacent in the original gel must have a dark line delineating the boundary between the gels. Loading controls (eg, GAPDH, actin) must be run on the same blot. Sample processing controls run on different gels must be identified as such, and distinctly from loading controls.

Cropped gels and blots in the paper must retain important bands, and Carcinogenesis recommends at least six bandwidths above and below the band under investigation.

Overexposure may mask additional bands and high-contrast gels and blots are therefore discouraged. Gray backgrounds are expected as the norm. If high contrast is unavoidable then multiple exposures should be presented in supplementary information.

For quantitative comparisons, appropriate reagents, controls and imaging methods with linear signal ranges should be used.

Illustrations

All illustrations (line drawings and photographs) should be referred to in the text as Figure 1 etc., abbreviated to 'Fig. 1.' only in the figure legend. Wherever possible, figures will be sized to fit the width of a single column of text, i.e., 88mm wide. The maximum width of a double column figure is 183mm, the maximum depth is 240mm. Figures with low density data will all be single column width. Please consider the overall page dimensions and layout, and the final

reduction necessary for printing. Figures must be at a minimum resolution of 600 d.p.i. for line drawings (black and white) and 300 d.p.i. for colour or greyscale. Any lettering should be ~2mm in height in the printed figure (after reduction) and should be in proportion to the overall dimensions of the drawing. Labels should not be disproportionally large and should show up clearly against the background.

Photographs

Wherever possible, these must be submitted in the desired final size so that reduction can be avoided. Ideally, photographs should fit either a single column (88mm) or a double column (183mm). Photographs should be of sufficiently high quality with respect to detail, contrast and fineness of grain to withstand the inevitable loss of contrast and detail inherent in the printing process. Please indicate the magnification by a rule on the photographs.

Colour figures

There is a special charge for the inclusion of colour figures. The cost is £350 / \$600 per figure. (For cost purposes, the definition of a single figure is artwork that can be processed as a unit and printed on a single page without intervening type. Authors should note the potential cost savings inherent in this definition; for example, two *consecutive* half-page colour figures mounted as a composite and printed on one page, with both legends below or on the facing page, would be treated as *one* figure.) If there is a choice of colours on a schematic, please choose clearly distinct colours (e.g. not two shades of blue) and avoid black backgrounds if possible.

Line drawings

Please provide clear, sharp prints, suitable for reproduction as submitted. No additional artwork, redrawing or typesetting will be done. Therefore, all labelling should preferably be made with a lettering set. Ensure that the size of lettering is in proportion with the overall dimensions of the drawing. Ideally, line drawings should be submitted in the desired final size to avoid reduction (maximum dimensions 248 x 185 mm including legends) and should fit either a single (88 mm) or a double column width (185 mm). If submitting line drawings which require reduction, please check that the lettering will be clearly legible after reduction to the size at which it will be printed. After reduction, letters should not be smaller than 1.5 mm in height.

Figure legends

Figure legends should follow the reference list. Define all symbols and abbreviations used in the figure. Common abbreviations and others in the preceding text should not be redefined in the legend.

Conventions

The journal follows the conventions of the *CBE Style Manual* (Council of Biology Editors, Bethesda, MD, 1983, 5th edn).

Follow *Chemical Abstracts* and its indexes for chemical names. For guidance follow the recommendations issued by the IUPAC-IUB Commission on Bio-chemical Nomenclature, as given in *Biochemical Nomenclature and Related*

Documents, published by the Biochemical Society, UK. For enzymes, use the recommended name assigned by the IUPAC-IUB Commission on Bio-chemical Nomenclature, 1978, as given in *Enzyme Nomenclature*, published by Academic Press, New York (NY), 1980. Where possible, use recommended SI (System International) units.

Abbreviations

Restrict the use of abbreviations to SI symbols and those recommended by the IUPAC. Abbreviations should be defined in brackets after their first mention in the text. Standard units of measurements and chemical symbols of elements may be used without definition.

Policy concerning availability of materials

It is understood that by publishing a paper in *Carcinogenesis* the authors agree to make freely available to colleagues in academic research any of the cells, nucleic acids, antibodies, animals etc. that were used in the research reported and that are not available from commercial suppliers.

License to publish and conflict of interest

Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence to publish form.

Please note that by submitting an article for publication you confirm that you are the corresponding/submitting author and that Oxford University Press ("OUP") may retain your email address for the purpose of communicating with

you about the article. You agree to notify OUP immediately if your details change. If your article is accepted for publication OUP will contact you using the email address you have used in the registration process. Please note that OUP does not retain copies of rejected articles.

It is a condition of publication in the Journal that authors grant an exclusive licence to Oxford University Press. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will also allow the article to be as widely disseminated as possible. In giving this exclusive licence, authors may use their own material in other publications provided that the Journal is notified and acknowledged as the original place of publication, and that Oxford University Press is notified in writing and in advance.

At the point of submission, Carcinogenesis Journal's policy requires that each author reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated - including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. When considering whether you should declare a conflicting interest or connection please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it?

As an integral part of the online submission process, Corresponding authors are required to confirm whether they or their co-authors have any

conflicts of interest to declare and to provide details of these. If the Corresponding author is unable to confirm this information on behalf of all co-authors, the authors in question will then be required to submit a [Conflict of Interest form](#) to the Editorial Office. It is the Corresponding author's responsibility to ensure that all authors adhere to this policy. If the manuscript is published, Conflict of Interest information will be communicated in a statement in the published paper.

Offprints

The publishers supply a link to the paper's URL free of charge. Printed offprints of the article or copies of the issue in which the article is published can be ordered using the Oxford Journals Author Services site. You will receive a link to this site from the Production office when your paper has been accepted for publication in the journal. Late orders submitted after the journal is printed are subject to increased prices.

Orders from the UK will be subject to the current UK VAT charge. For orders from elsewhere in the EU you or your institution should account for VAT by way of a reverse charge. Please provide us with your or your institution's VAT number.

Open access option for authors

Carcinogenesis authors have the option to publish their paper under the Oxford Open initiative; whereby, for a charge, their paper will be made freely available online immediately upon publication. After your manuscript is accepted the corresponding author will be required to accept a mandatory licence to publish

agreement. As part of the licensing process you will be asked to indicate whether or not you wish to pay for open access. If you do not select the open access option, your paper will be published with standard subscription-based access and you will not be charged. Oxford Open articles are published under a Creative Commons licence.

RCUK/Welcome Trust funded authors publishing in Carcinogenesis can use the Creative Commons Attribution licence (CC BY) for their articles.

You can pay Open Access charges using our Author Services site. This will enable you to pay online with a credit/debit card, or request an invoice by email or post. The applicable open access charges vary according to which Creative Commons licence you select. The open access charges are as follows.

Orders from the UK will be subject to the current UK VAT charge. For orders from the rest of the European Union, OUP will assume that the service is provided for business purposes. Please provide a VAT number for yourself or your institution, and ensure your account for your own local VAT correctly.

Third-party content in open access papers

If you will be publishing your paper under an Open Access licence but it contains material for which you do not have Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material: *Title of content; author, original publication, year of original publication, by permission of [rights holder]. This image/content is not covered by the terms*

of the Creative Commons licence of this publication. For permission to reuse, please contact the rights holder.

Author self-archiving/public access policy from May 2005

For information about this journal's policy, please visit our [Author Self-Archiving policy page](#).

Crossref funding data registry & funding

In order to meet your funding requirements authors are required to name their funding sources, or state if there are none, during the submission process. For further information on this process or to find out more about the CHORUS initiative please click [here](#). Details of all funding sources for the work in question should be given in a separate section entitled 'Funding'. This should appear before the 'Acknowledgements' section.

The following rules should be followed:

The sentence should begin: 'This work was supported by ...'

- The full official funding agency name should be given, i.e. 'National Institutes of Health', not 'NIH' (full RIN-approved list of UK funding agencies) Grant numbers should be given in brackets as follows: '[grant number xxxx]'
- Multiple grant numbers should be separated by a comma as follows: '[grant numbers xxxx, yyyy]'

- Agencies should be separated by a semi-colon (plus 'and' before the last funding agency)
- Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number 'to [author initials]'.

An example is given here: 'This work was supported by the National Institutes of Health [AA123456 to C.S., BB765432 to M.H.]; and the Alcohol & Education Research Council [hfygr667789].'